Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Natamycin

FDA-approved product (suspension, ophthalmic), marketed as Natacyn.

Registered studies
15
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Natamycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Eye infection
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antiinfectives and antiseptics for local oral treatment; Antibiotics
FDA pharmacologic class
Polyene Antimicrobial FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC A01AB10; WHO ATC A07AA03; WHO ATC D01AA02; WHO ATC G01AA02; WHO ATC S01AA10; FDA class Polyene Antimicrobial

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

15registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Natamycin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Natamycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • RB-PDT for Fusarium Keratitis: The LUMIERE Study

    NCT07743489 · start 2027-01

    Registered record
    Registry ID
    NCT07743489
    Conditions
    Fusarium Keratitis
    Interventions
    Rose Bengal Photodynamic Therapy; Sham RB-PDT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-01
    Completion
    2030-01
    Enrolment
    434

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFusarium Keratitis
    InterventionRose Bengal Photodynamic Therapy; Sham RB-PDT
    PhasePhase 3
    Registry statusNot yet recruiting

  • Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis

    NCT06463678 · start 2026-08-01

    Registered record
    Registry ID
    NCT06463678
    Conditions
    Fungal Keratitis
    Interventions
    IVIEW-1201; NATACYN®
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2027-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Keratitis
    InterventionIVIEW-1201; NATACYN®
    PhasePhase 2
    Registry statusNot yet recruiting

  • Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A

    NCT06658002 · start 2025-09-01

    Registered record
    Registry ID
    NCT06658002
    Conditions
    Fungal Keratitis; Corneal Ulcer
    Interventions
    Cyclosporine A; Placebo Comparator: Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-09-01
    Completion
    2027-09-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Keratitis; Corneal Ulcer
    InterventionCyclosporine A; Placebo Comparator: Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis

    NCT06411314 · start 2022-12-29

    Registered record
    Registry ID
    NCT06411314
    Conditions
    Vulvovaginal Candidiasis, Genital
    Interventions
    Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories; Lactulose 300 mg vaginal suppositories; Pimafucin® (natamycin) 100 mg vaginal suppositories
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-12-29
    Completion
    2023-09-22
    Enrolment
    218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVulvovaginal Candidiasis, Genital
    InterventionNatamycin + Lactulose 100 mg + 300 mg vaginal suppositories; Lactulose 300 mg vaginal suppositories; Pimafucin® (natamycin) 100 mg vaginal suppositories
    PhasePhase 3
    Registry statusCompleted

  • Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

    NCT05110001 · start 2022-08-03

    Registered record
    Registry ID
    NCT05110001
    Conditions
    Acanthamoeba Keratitis; Fungal Keratitis
    Interventions
    Moxifloxacin Ophthalmic; Chlorhexidine Gluconate; Natamycin; Rose Bengal; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-08-03
    Completion
    2025-06-30
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcanthamoeba Keratitis; Fungal Keratitis
    InterventionMoxifloxacin Ophthalmic; Chlorhexidine Gluconate; Natamycin; Rose Bengal +1 more
    PhasePhase 3
    Registry statusCompleted

  • The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study

    NCT05655689 · start 2021-12-31

    Registered record
    Registry ID
    NCT05655689
    Conditions
    Bacterial Keratitis; Fungal Keratitis; Mixed Bacterial and Fungal Keratitis; Microbial Keratitis
    Interventions
    Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution; Ceftazidime 5% + vancomycin 5%; Gentamicin 1.4% + vancomycin 5%; Natamycin 5% Oph Susp; Voriconazole 1%; Natamycin 5% + voriconazole 1%; Natamycin 5%+ ceftazidime 5% + vancomycin 5%; Voriconazole 1% + ceftazidime 5% + vancomycin 5%
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-12-31
    Completion
    2023-01-01
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Keratitis; Fungal Keratitis; Mixed Bacterial and Fungal Keratitis; Microbial Keratitis
    InterventionMoxifloxacin Ophthalmic 0.5% Ophthalmic Solution; Ceftazidime 5% + vancomycin 5%; Gentamicin 1.4% + vancomycin 5%; Natamycin 5% Oph Susp +4 more
    PhaseNot recorded
    Registry statusCompleted

  • Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis

    NCT03230058 · start 2017-01-01

    Registered record
    Registry ID
    NCT03230058
    Conditions
    Infection, Fungal
    Interventions
    Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2017-01-01
    Completion
    2018-09-30
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Fungal
    InterventionGroup 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers

    NCT02731638 · start 2016-09

    Registered record
    Registry ID
    NCT02731638
    Conditions
    Corneal Ulcer; Fungal Keratitis
    Interventions
    Intrastromal voriconazole; Natamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-09
    Completion
    2018-07
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcer; Fungal Keratitis
    InterventionIntrastromal voriconazole; Natamycin
    PhasePhase 3
    Registry statusCompleted

  • Cross-linking for Corneal Ulcers Treatment Trial

    NCT02570321 · start 2015-11

    Registered record
    Registry ID
    NCT02570321
    Conditions
    Corneal Ulcer; Infectious Keratitis; Bacterial Ulcer; Fungal Ulcer
    Interventions
    Corneal Cross-linking; Anti Fungal Drug
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11
    Completion
    2019-03-19
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcer; Infectious Keratitis; Bacterial Ulcer; Fungal Ulcer
    InterventionCorneal Cross-linking; Anti Fungal Drug
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis

    NCT02865876 · start 2015-06

    Registered record
    Registry ID
    NCT02865876
    Conditions
    Keratitis
    Interventions
    Accelerated Corneal Cross-linking
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-06
    Completion
    2017-03
    Enrolment
    264

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratitis
    InterventionAccelerated Corneal Cross-linking
    PhasePhase 3
    Registry statusUnknown

  • Clinical & Visual Outcomes of Collagen Cross Linking for Fungal Keratitis

    NCT02328053 · start 2014-02

    Registered record
    Registry ID
    NCT02328053
    Conditions
    Mycotic Corneal Ulcer
    Interventions
    collagen crosslinking group; Topical anti-fungal therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2014-02
    Completion
    2015-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycotic Corneal Ulcer
    Interventioncollagen crosslinking group; Topical anti-fungal therapy
    PhaseNot applicable
    Registry statusUnknown

  • The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

    NCT00997035 · start 2010-05

    Registered record
    Registry ID
    NCT00997035
    Conditions
    Corneal Ulcer; Eye Infections, Fungal
    Interventions
    Voriconazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-05
    Completion
    2016-03
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcer; Eye Infections, Fungal
    InterventionVoriconazole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Mycotic Ulcer Treatment Trial I

    NCT00996736 · start 2010-04

    Registered record
    Registry ID
    NCT00996736
    Conditions
    Corneal Ulcer; Eye Infections, Fungal
    Interventions
    Natamycin; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-04
    Completion
    2012-07
    Enrolment
    323

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcer; Eye Infections, Fungal
    InterventionNatamycin; Voriconazole
    PhasePhase 3
    Registry statusCompleted

  • A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine

    NCT00516399 · start 2008-03

    Registered record
    Registry ID
    NCT00516399
    Conditions
    Fungal Keratitis
    Interventions
    povidone-iodine 1.25% ophthalmic solution; natamycin ophthalmic suspension, USP 5%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-03
    Completion
    2010-12
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Keratitis
    Interventionpovidone-iodine 1.25% ophthalmic solution; natamycin ophthalmic suspension, USP 5%
    PhasePhase 3
    Registry statusTerminated

  • Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer

    NCT00557362 · start 2007-11

    Registered record
    Registry ID
    NCT00557362
    Conditions
    Fungal Keratitis
    Interventions
    Natamycin 5%; Voriconazole; Corneal de-epithelialization
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-11
    Completion
    2008-08
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Keratitis
    InterventionNatamycin 5%; Voriconazole; Corneal de-epithelialization
    PhasePhase 1 / Phase 2
    Registry statusCompleted